Cold Spring Harbor Laboratory  
Contact Us | Faculty & Staff Directory
Harbor Transcript
Contact Public Affairs
We want to hear from you.
Contact Us
Follow us on
Become a fan on Facebook!twitterView our Flickr photos!Visit CSHL's YouTube channel!Find a CSHL RSS feed!Sign up  for the CSHL Newsletter

Lumera Invited to Demonstrate its ProteomicProcessor™ at Cold Spring Harbor Laboratory

Three week Proteomics course to highlight Lumera’s technology to leading academic and pharmaceutical researchers

Bothell, WA., June 28 -- Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, announced today that it has been invited to demonstrate its ProteomicProcessor™ Biosensor at the 2006 Proteomics course at Cold Spring Harbor Laboratory. As one of eight National Cancer Institute-designated basic research centers in the U.S., Cold Spring Harbor hosts a series of short courses whereby academic and industrial scientists gather to learn the latest scientific advances and to be trained in new cutting edge technologies.

“ We are both excited and grateful for the opportunity to have our instrument platform included in this event,” said Tom Mino, Lumera CEO. “While this event gives us exposure to additional academic accounts, it also raises our profile in the pharmaceutical industry. Scientists from large pharmaceutical companies will have the opportunity to see our technology first hand.”

Lumera has begun presales activities for its ProteomicProcessor™ platform in anticipation of the product launch in the fourth quarter. In addition to the demonstration at Cold Spring Harbor, Lumera is ramping their sales and marketing activities which include a focus group of therapeutic antibody companies, presentations at leading biotechnology and pharmaceutical companies, and product presentation at leading conferences. In anticipation of the fourth quarter product launch, the company has begun to increase sales and marketing personnel, recently adding an Applications Scientist to support the growing user base.

About Lumera

Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit

About Cold Spring Harbor Laboratory

The Proteomics course at Cold Spring Harbor Laboratory ( is a three week intensive laboratory and lecture course focusing on two major themes in proteomics: protein profiling and functional proteomics. The course receives financial support from the Nation Cancer Institute and features world renowned instructors from academics and industry.

Cold Spring Harbor Laboratory is a private, non-profit basic research and educational institution. Under the leadership of Dr. Bruce Stillman, a member of the National Academy of Sciences and a Fellow of the Royal Society (London), some 400 scientists conduct groundbreaking research there in cancer, neurobiology, plant genetics and bioinformatics. Cold Spring Harbor Laboratory is one of eight National Cancer Institute-designated basic research centers in the U.S. and the only such center in the tri-state area.

Certain statements contained in this release are forward-lookingstatements that involve a number of risks and uncertainties. Factorsthat could cause actual results to differ materially from thoseprojected in the company's forward-looking statements include thefollowing: market acceptance of our technologies and products; ourability to obtain financing; our financial and technical resourcesrelative to those of our competitors; our ability to keep up withrapid technological change; government regulation of our technologies;our ability to enforce our intellectual property rights and protectour proprietary technologies; the ability to obtain additionalcontract awards and to develop partnership opportunities; the timingof commercial product launches; the ability to achieve key technicalmilestones in key products; and other risk factors identified fromtime to time in the company's SEC reports, including its Annual Reporton Form 10-K, and its Quarterly Reports on Form 10-Q.

For more information, visit
Bookmark and Share